title: Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting.
abstract: About 30% of renal cell carcinomas (RCC) will develop recurrence after surgery. Despite evidence for a significantly improved survival by autologous tumour cell vaccination therapy, the procedure has not become standard. Between August 1993 and December 1996, 1,267 RCC patients undergoing radical nephrectomy in 84 German hospitals were subsequently treated by autologous tumour cell vaccination therapy. The study group comprised 692 patients with complete follow-up (stages pT2-3, pNx-2, M0 based on the TNM classification, 4th edition). Subsequent propensity-score matching according to 7 defined criteria with 861 control patients undergoing nephrectomy alone without adjuvant treatment at the Carl-Thiem-Hospital Cottbus, resulted in 495 matched pairs. Overall and stage-specific survival rates were analysed after a median follow-up of 131 months. The 5- and 10-year overall survival (OS) rates were 80.6 and 68.9% in the vaccine group and 79.2 and 62.1% in the control group (p = 0.066). Patients with pT3 stage RCC revealed 5- and 10-year OS rates of 71.3 and 53.6% in the study group and 65.4 and 36.2% in the control group (p = 0.022). In multivariable analysis, patients in the vaccine group showed a significantly improved survival both in the whole study group (HR = 1.28, p = 0.030) and in the subgroup presenting with pT3 stage tumours (HR = 1.67, p = 0.011). Adjuvant treatment with autologous vaccination therapy resulted in a significantly improved overall survival in pT3 stage RCC patients, suggesting benefit especially in this subgroup. However, controlled clinical trials integrating the recent TNM classification and further risk constellations are required to define additional patient groups that may derive benefit from this treatment.
authors.affiliation: Department of Urology, St. Elisabeth Hospital Straubing, Germany. Matthias.May@klinikum-straubing.de
authors.forename: Matthias
authors.initials: M
authors.lastname: May
authors.forename: Sabine
authors.initials: S
authors.lastname: Brookman-May
authors.forename: Bernd
authors.initials: B
authors.lastname: Hoschke
authors.forename: Christian
authors.initials: C
authors.lastname: Gilfrich
authors.forename: Friederike
authors.initials: F
authors.lastname: Kendel
authors.forename: Susann
authors.initials: S
authors.lastname: Baxmann
authors.forename: Stefan
authors.initials: S
authors.lastname: Wittke
authors.forename: Stephan T
authors.initials: ST
authors.lastname: Kiessig
authors.forename: Kurt
authors.initials: K
authors.lastname: Miller
authors.forename: Manfred
authors.initials: M
authors.lastname: Johannsen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D057176:Compassionate Use Trials; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009392:Nephrectomy; D055815:Young Adult
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines